Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announced that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone  technology for the formulation of fast acting insulin analog formulated with the BioChaperone technology. Consequently, the two companies have terminated the collaboration.

“We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone technology” said Gerard Soula, president and CEO, Adocia.

“Our plan is to test a BioChaperone insulin analog formulation on type I diabetic patients. For this, we intend to conduct a clinical trial, before year end in Germany, on one or more formulations of insulin analog. This trial will be carried out in parallel to the one already scheduled with HinsBet, our formulation of human insulin” said Olivier Soula, deputy general manager and director R&D, Adocia.

Through its BioChaperone state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.

Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.